Table 7.
NP-based combined PTT/PDT/RT.
| Type of NPs | Payload | PTT/PDT | In vitro anti-cancer effect | Particles injection dosage of in vivo anti-cancer study | In vivo anti-cancer effect | Reference |
|---|---|---|---|---|---|---|
| Silica-coated bismuth NPs | H2O2-responsive N-benzylaminoferrocene-based prodrug | PTT | Photo- and H2O2-induced GSH-depletion and apoptosis | 50 μL (in terms of bismuth NPs: 2 mg/mL) | PTT-induced hypoxia alleviation. Sequential PTT and RT inhibited 4T1 tumor growth | [277] |
| Liposomal iridium nanocrystals | N/A | PTT | RT-induced DNA damage on 4T1 cells | 6 mg/kg (equivalent Iridium content) | PAI, and inhibited 4T1 tumor growth by RT + PTT | [278] |
| 2D silicene nanosheets decorated by Pt and lipids | N/A | PTT | Oxygenation of 4T1 cells catalyzed by Pt. Combined PTT and RT induced cell death. | 15 mg/kg | 4T1 tumor hypoxia alleviation and tumor growth inhibition | [281] |
| Cu3BiSe3 NPs modified by poly(vinylpyrollidone) | N/A | PTT | ROS generation and Hela cell killing effects | 25 μL (4 mg/mL) | Inhibited Hela tumor growth and metastasis | [282] |
| Bi2Se3 hollow nanocubes modified by HA | Gambogic acid | PTT | 4T1 cell HSP expression inhibition after PTT, and cell killing effects | 100 μL (5 mg/mL) | 4T1 tumor inhibition by mild hyperthermia (∼45 °C) + RT | [288] |
| PEG-modified nanoscintillator composed of Gd2(WO4)3:Tb NPs | Merocyanine 540 | PDT | Apoptosis of 4T1 | 30 μL (7.5 mg/mL) | Dual-modal CT/MRI imaging and 4T1 tumor growth inhibition | [292] |
| Lipids coated Hf-incorporated AIE photosensitizer NP | N/A | PDT | Bioorthogonal coupling of NPs on 4T1 cell membrane followed by X-ray irradiation | 25 μL (tetraacetylated N-azidoacetylmannosamine: 0.08 mg)+ 6 mg/kg (equivalent Hf content) | In vivo targeting by bioorthogonal click chemistry and 4T1 tumor growth inhibition | [294] |
| RBCM-coated Algae | Chlorophyll | PDT | Intracellular oxygen level increase and 4T1 cell killing by RT + laser irradiation | 150 μL (1 × 106 RBCM-Algae/mL) | 4T1 tumor inhibition by ROS generation. HIF-α and VEGF expression decrease. | [296] |
| MOFs, based containing Hf or Ru | N/A | PDT | Mitochondria targeting and apoptosis of MC38 cells | 0.2 μmol (equivalent dose of [DBB-Ru bis (2,2′-bipyridine)(5,5′-di(4-benzoato)-2,2′-bipyridine)Ru (II) chloride]) |
MC38 tumor growth inhibition | [302] |
| MOFs, based on Hf clusters and porphyrin ligands | A small-molecule IDO inhibitor | PDT | Intracellular 1O2 generation and cell growth inhibition | 0.11 mg | Ultra-low X-ray irradiation (0.5 Gy, 3 daily doses), eliminated tumor efficiently on CT26, U87MG and TUBO models | [306] |